Pontifax Management 4 G.p. (2015) Ltd. - Net Worth and Insider Trading
Pontifax Management 4 G.p. (2015) Ltd. Net Worth
The estimated net worth of Pontifax Management 4 G.p. (2015) Ltd. is at least $260 Million dollars as of 2024-05-15. Pontifax Management 4 G.p. (2015) Ltd. is the 10% Owner of Keros Therapeutics Inc and owns about 4,794,507 shares of Keros Therapeutics Inc (KROS) stock worth over $260 Million. Pontifax Management 4 G.p. (2015) Ltd. is also the 10% Owner of Eloxx Pharmaceuticals Inc and owns about 600 shares of Eloxx Pharmaceuticals Inc (ELOX) stock worth over $515. Details can be seen in Pontifax Management 4 G.p. (2015) Ltd.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Pontifax Management 4 G.p. (2015) Ltd. has not made any transactions after 2020-11-17 and currently still holds the listed stock(s).
Transaction Summary of Pontifax Management 4 G.p. (2015) Ltd.
Pontifax Management 4 G.p. (2015) Ltd. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Pontifax Management 4 G.p. (2015) Ltd. owns 3 companies in total, including Eloxx Pharmaceuticals Inc (ELOX) , Keros Therapeutics Inc (KROS) , and 89bio Inc (ETNB) .
Insider Ownership Summary of Pontifax Management 4 G.p. (2015) Ltd.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ELOX | Eloxx Pharmaceuticals Inc | 2021-05-13 | 10 percent owner |
| KROS | Keros Therapeutics Inc | 2020-11-17 | 10 percent owner |
| ETNB | 89bio Inc | 2019-11-08 | 10 percent owner |
Pontifax Management 4 G.p. (2015) Ltd. Latest Holdings Summary
Pontifax Management 4 G.p. (2015) Ltd. currently owns a total of 2 stocks. Among these stocks, Pontifax Management 4 G.p. (2015) Ltd. owns 4,794,507 shares of Keros Therapeutics Inc (KROS) as of November 17, 2020, with a value of $260 Million and a weighting of 100%. Pontifax Management 4 G.p. (2015) Ltd. also owns 600 shares of Eloxx Pharmaceuticals Inc (ELOX) as of June 24, 2019, with a value of $515 and a weighting of 0%.
Latest Holdings of Pontifax Management 4 G.p. (2015) Ltd.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics Inc | 2020-11-17 | 4,794,507 | 54.31 | 260,401,661 |
| ELOX | Eloxx Pharmaceuticals Inc | 2019-06-24 | 600 | 0.86 | 515 |
Holding Weightings of Pontifax Management 4 G.p. (2015) Ltd.
Pontifax Management 4 G.p. (2015) Ltd. Form 4 Trading Tracker
According to the SEC Form 4 filings, Pontifax Management 4 G.p. (2015) Ltd. has made a total of 2 transactions in Keros Therapeutics Inc (KROS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Keros Therapeutics Inc is the acquisition of 60,000 shares on November 17, 2020, which cost Pontifax Management 4 G.p. (2015) Ltd. around $3 Million.
According to the SEC Form 4 filings, Pontifax Management 4 G.p. (2015) Ltd. has made a total of 1 transactions in Eloxx Pharmaceuticals Inc (ELOX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Eloxx Pharmaceuticals Inc is the acquisition of 5,000 shares on June 24, 2019, which cost Pontifax Management 4 G.p. (2015) Ltd. around $2 Million.
Insider Trading History of Pontifax Management 4 G.p. (2015) Ltd.
- 1
Pontifax Management 4 G.p. (2015) Ltd. Trading Performance
GuruFocus tracks the stock performance after each of Pontifax Management 4 G.p. (2015) Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pontifax Management 4 G.p. (2015) Ltd. is 2.34%. GuruFocus also compares Pontifax Management 4 G.p. (2015) Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Pontifax Management 4 G.p. (2015) Ltd. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Pontifax Management 4 G.p. (2015) Ltd.'s insider trading performs compared to the benchmark.
Performance of Pontifax Management 4 G.p. (2015) Ltd.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 13.56 | | | | | |
| Relative Return to S&P 500(%) | 10.91 | | | | | |
Pontifax Management 4 G.p. (2015) Ltd. Ownership Network
Pontifax Management 4 G.p. (2015) Ltd. Owned Company Details
What does Eloxx Pharmaceuticals Inc do?
Who are the key executives at Eloxx Pharmaceuticals Inc?
Pontifax Management 4 G.p. (2015) Ltd. is the 10 percent owner of Eloxx Pharmaceuticals Inc. Other key executives at Eloxx Pharmaceuticals Inc include HEAD OF R&D Vijay Modur , director & PRESIDENT AND CEO Sumit Aggarwal , and Chief Financial Officer Daniel E. Geffken .
Eloxx Pharmaceuticals Inc (ELOX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Eloxx Pharmaceuticals Inc (ELOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eloxx Pharmaceuticals Inc (ELOX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Eloxx Pharmaceuticals Inc (ELOX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eloxx Pharmaceuticals Inc Insider Transactions
Pontifax Management 4 G.p. (2015) Ltd. Mailing Address
Above is the net worth, insider trading, and ownership report for Pontifax Management 4 G.p. (2015) Ltd.. You might contact Pontifax Management 4 G.p. (2015) Ltd. via mailing address: 14 Shenkar Street, Beit Ofek, Herzliya Pituach L3 46140.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
